StockData

Vicarious Surgical Inc. (RBOT) stock

RBOTOTCOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Apr 30, 2026Score 5/30
$0.02+0.00 (+11.11%)

Close on Oct 19, 2026Market cap $142.41KP/E –Yield –

Vicarious Surgical r&d expenses

Research and development expenses are spending on new products and technology.

Vicarious Surgical's R&D Expenses for the twelve months ending Mar 31, 2026 was $29.23M, down 26.2% year over year. For fiscal 2025 it was $33.60M, down 16.3% from the year before. The highest annual figure on record is $47.58M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$33.60M-16.3%
FY2024Dec 31, 2024$40.16M-15.6%
FY2023Dec 31, 2023$47.58M+8.4%
FY2022Dec 31, 2022$43.90M+99.0%
FY2021Dec 31, 2021$22.06M+125.2%
FY2020Dec 31, 2020$9.80M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$5.04M-46.5%
Q4 FY2025Dec 31, 2025$7.14M-15.6%
Q3 FY2025Sep 30, 2025$7.99M-26.0%
Q2 FY2025Jun 30, 2025$9.05M-17.2%
Q1 FY2025Mar 31, 2025$9.42M-5.5%
Q4 FY2024Dec 31, 2024$8.46M-0.1%
Q3 FY2024Sep 30, 2024$10.80M-17.2%
Q2 FY2024Jun 30, 2024$10.92M-14.1%
Q1 FY2024Mar 31, 2024$9.97M-25.4%
Q4 FY2023Dec 31, 2023$8.47M-28.7%
Q3 FY2023Sep 30, 2023$13.04M+7.6%
Q2 FY2023Jun 30, 2023$12.71M+26.4%
Q1 FY2023Mar 31, 2023$13.36M+35.6%
Q4 FY2022Dec 31, 2022$11.88M+28.3%
Q3 FY2022Sep 30, 2022$12.12M+133.6%
Q2 FY2022Jun 30, 2022$10.06M+150.9%
Q1 FY2022Mar 31, 2022$9.85M+173.0%
Q4 FY2021Dec 31, 2021$9.26M+212.1%
Q3 FY2021Sep 30, 2021$5.19M–
Q2 FY2021Jun 30, 2021$4.01M–
Q1 FY2021Mar 31, 2021$3.61M–
Q4 FY2020Dec 31, 2020$2.97M–

More Vicarious Surgical figures

See a number that looks wrong?